Evaluation of the effect of Atorvastatin in diabetic type 2 patients in the morning and evening

Evaluation of the effect of Atorvastatin administration time in the morning and evening on lipid profile in patients with type 2 diabetes

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT20211211053359N1

Enrollment

Registered

2022-09-26

Start date

2022-09-21

Completion date

Unknown

Last updated

2022-11-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Evaluation of the effect of Atorvastatin administration time in the morning and evening on lipid profile in patients with type 2 diabetes.

Interventions

Intervention 1: Intervention group:In this randomized clinical trial, participants will be randomly assigned to two separate groups in the first group of atorvastatin tablets produced by Sobhan Pharma

Eligibility

Sex/Gender

All

Age

40 Years to No maximum

Inclusion criteria

Inclusion criteria: Any diabetic patient over the age of 40

Exclusion criteria

Exclusion criteria: People with renal failure Patient with cancer People who have used lipid lowering drugs before

Design outcomes

Primary

Measure	Time frame
Blood levels of lipid profiles. Timepoint: At the beginning of the study and after 4 weeks. Method of measurement: Blood lipid profile (TG, HDL, LDL).	—

Secondary

Measure	Time frame
Gastrointestinal complication. Timepoint: At the beginning of the administration of the drug on a daily basis. Method of measurement: Gastrointestinal complications will be recorded by the patients in the corresponding checklist on a daily basis.;Musculoskeletal complications. Timepoint: At the beginning of the administration of the drug on a daily basis. Method of measurement: Musculoskeletal complications will be recorded by the patients in the corresponding checklist on a daily basis.	—

Measure

Time frame

Gastrointestinal complication. Timepoint: At the beginning of the administration of the drug on a daily basis. Method of measurement: Gastrointestinal complications will be recorded by the patients in the corresponding checklist on a daily basis.;Musculoskeletal complications. Timepoint: At the beginning of the administration of the drug on a daily basis. Method of measurement: Musculoskeletal complications will be recorded by the patients in the corresponding checklist on a daily basis.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSepide Tavanaeifard

Babol University of Medical Sciences

s.tavanaeifard@mubabol.ac.ir+98 11 3223 8301

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026